A preview of the new video from Hawaii Crop Improvement Association (HCIA) highlighting the benefits that agricultural biotechnology is having on Hawaii and the world. Through interviews with local scientists, farmers and economists, “Seeds of Promise” dispels the emotion-laden myths and fear-mongering perpetuated by anti-biotech activists. Biotechnology is a powerful tool that has enabled farmers and families throughout the world to grow bountiful, nutritious food in a more environmentally friendly manner. For more information, visit www.hciaonline.com
The Cystic Fibrosis Foundation strives to advance the search for a cure for CF by funding promising scientific research at medical centers and biotech companies nationwide. Frank Deford narrates this look at the Cystic Fibrosis Foundation’s innovative approach to moving new treatments for CF into a pipeline that promises a better quality of life for all CF patients.
Product Description This digital document is an article from Community College Week, published by Autumn Publishing on April 20, 2009. The length of the article is 682 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.
Citation Details Title: Maryland College chief leads effort to seize promise of biotech jobs.(around the nation) Author: Gale Reference Team Publication:Community College Week (Newspaper) Date: April 20, 2009 Publisher: Autumn Publishing Volume: 21 Issue: 17 Page: 3(2)
Notes: Brand New from Publisher. No Remainder Mark.
Product Description Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of biotech’s problems; he offers the most sophisticated analysis yet on how the industry works. And he provides clear prescriptions for companies, investors, and policymakers seeking ways to improve the industry’s performance.
According to Pisano, the biotech industry’s problems stem from its special character as a science-based business. This character poses three unique business challenges: 1) how to finance highly risky investments under profound uncertainty and long time horizons for R&D, 2) how to learn rapidly enough to keep pace with advances in drug science knowledge, and 3) how to integrate capabilities across a broad spectrum of scientific and technological knowledge bases.
The key to fixing the industry? Business models, organizational structures, and financing arrangements that place greater emphasis on integration and long-term learning over shorter-term “monetization” of intellectual property. Pisano maintains that all industry players—biotech firms, investors, universities, pharmaceutical companies, government regulators—can play a role in righting the industry. The payoff? Valuable improvements in health care, and a shinier future for human well-being.
